Open-access, model-informed tools translating pharmacometric research into individualized drug therapy. Developed at the Chair of Clinical Pharmacy, Saarland University.
Our tools integrate population pharmacokinetic (popPK) and physiologically-based pharmacokinetic (PBPK) models with patient-specific data — genetics, co-medications, and clinical parameters — to support evidence-based dosing decisions. They are intended to support, not replace, clinical judgment.
Drug-Drug-Gene Interaction Dose Optimization
A key deliverable of the EU Horizon-funded SafePolyMed consortium (Grant No. 101057639), coordinated by Prof. Dr. Thorsten Lehr. SafePolyMed unites twelve European institutions to improve medication safety in polypharmacy patients through machine learning on real-world data, pharmacogenomic profiling, and mechanistic PBPK modeling.
The DSS translates this research into a practical clinical tool. It integrates PBPK models for imatinib, paroxetine, tacrolimus, and voriconazole, accounting for CYP450 polymorphisms (CYP2C19, CYP2D6, CYP3A5) and drug-drug interactions. Clinicians enter patient demographics, genetic phenotypes, measured concentrations, and dosing histories to receive model-informed dose adaptation recommendations with downloadable reports.
Platelet Engraftment Predictor after HSCT
A prediction tool for platelet engraftment following hematopoietic stem cell transplantation (HSCT). Using patient-specific clinical data — conditioning regimen, donor type, ATG dosing, serial platelet counts, and transfusion history — it forecasts individual platelet recovery trajectories.
This supports transplant clinicians in anticipating engraftment timing, identifying patients at risk of delayed recovery, and optimizing post-transplant management.
TDM Support for Inflammatory Bowel Disease
Predicts serum infliximab concentrations in patients with Crohn's disease and ulcerative colitis. Clinicians can simulate different dose and interval combinations, model stepwise dose escalation, and evaluate target trough concentration attainment.
The tool accepts patient dosing data and generates concentration-time profiles with downloadable reports to support therapeutic drug monitoring (TDM) workflows.
DDGI-Aware Statin Dose Adjustment
Uses a PBPK model network to simulate simvastatin exposure across the 5–80 mg dose range. Accounts for drug-drug interactions (clarithromycin, itraconazole, gemfibrozil, rifampicin) and genetic polymorphisms in SLCO1B1, ABCG2, and CYP3A5.
Calculates dose adjustments to maintain equivalent systemic exposure when perpetrator drugs or genetic risk factors are present — supporting safe and effective statin therapy.
Malaria Prevention in Pregnancy
Models mefloquine pharmacokinetics in pregnant women receiving intermittent preventive treatment for malaria (IPTp). Based on clinical trial data from 264 pregnant women, it predicts concentration-time profiles for both mefloquine enantiomers and the carboxy-metabolite in maternal and umbilical cord blood.
Supports up to 20 dosing events with interindividual variability (95% CI) and export to PDF, Word, or HTML.
Anticoagulation Optimization — RE-LY Trial
Supports individualized dosing of dabigatran etexilate, a direct thrombin inhibitor for stroke prevention in non-valvular atrial fibrillation and VTE treatment. Based on a popPK model from over 9,000 patients in the landmark RE-LY trial.
By relating predicted concentrations to clinical outcomes (ischemic stroke, major bleeding), it helps identify patients who benefit from dose adjustments — particularly with renal impairment or P-glycoprotein inhibitors.